ICCC

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

Retrieved on: 
水曜日, 5月 8, 2024
Corporation, Health, ICCC, Interest

The Company is planning to host a conference call the next morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the unaudited financial results.

Key Points: 
  • The Company is planning to host a conference call the next morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the unaudited financial results.
  • This date has been pushed back five days from the original date of May 10, 2024.
  • The Company anticipates no change to the preliminary sales results for the first quarter ended March 31, 2024 that were disclosed on April 9, 2024.
  • The Company expects to file its Quarterly Report on Form 10-Q after the market closes on May 14, 2024.

2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners

Retrieved on: 
水曜日, 4月 17, 2024
Education, ICCC, ICIC, Small business, City, Traction, Artificial intelligence, Growth, Curriculum, Seriousness, Initiative, Acquisition, Economic development, Marketing, Walking, Management

This year, the ICCC program is placing a heightened focus on addressing the specific challenges identified by small business owners as critical roadblocks to their growth.

Key Points: 
  • This year, the ICCC program is placing a heightened focus on addressing the specific challenges identified by small business owners as critical roadblocks to their growth.
  • “The ICCC program is a transformative force for small businesses in underserved communities.
  • ICCC will also host a U.S. National Latinx Cohort entirely in Spanish and a specialty program for larger B2B companies in Connecticut.
  • For more information or to speak with an ICCC subject matter expert, please contact Indhira Taveras at [email protected] or 617-238-3030.

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Retrieved on: 
火曜日, 2月 27, 2024
Total, Investment, FDA, Marketing, First, Risk, Health, Security (finance), Farm, ICCC

“Our unaudited, preliminary product sales for the fourth quarter of 2023 were first reported on January 8, 2024,” commented Michael F. Brigham, President and CEO of ImmuCell.

Key Points: 
  • “Our unaudited, preliminary product sales for the fourth quarter of 2023 were first reported on January 8, 2024,” commented Michael F. Brigham, President and CEO of ImmuCell.
  • “We have no changes to those figures.”
    Total sales during the three-month period ended December 31, 2023 were 30% above the comparable period ended December 31, 2022.
  • Fourth quarter 2023 production was limited by lower output during the month of October, which was caused by a previously disclosed contamination event in September 2023.
  • EBITDA of approximately ($2.6) million during the year ended December 31, 2023 is in contrast to EBITDA of $350,000 during the year ended December 31, 2022.

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Retrieved on: 
金曜日, 2月 16, 2024
Interest, Health, ICCC, Corporation, Annual report

The Company has scheduled a conference call the next morning, Wednesday, February 28, 2024, at 9:00 AM ET to review its 2023 unaudited financial results.

Key Points: 
  • The Company has scheduled a conference call the next morning, Wednesday, February 28, 2024, at 9:00 AM ET to review its 2023 unaudited financial results.
  • This date has been pushed back six days from the original date first announced on January 8, 2024.
  • Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET.
  • The Company anticipates no change to the preliminary sales results for the fourth quarter and year ended December 31, 2023 that were disclosed on January 8, 2024.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Retrieved on: 
月曜日, 11月 13, 2023
First, EBITDA, Security (finance), Investment, Risk, Press release, FDA, Marketing, ICCC, Health, Rare-earth element, Satellite navigation device, Cryptocurrency, Reinsurance

PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.

Key Points: 
  • PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.
  • “Our unaudited, preliminary product sales for the third quarter of 2023 were first reported on October 5, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell.
  • Product sales increased by 13%, or $600,000, to $5.4 million during the three-month period ended September 30, 2023 compared to $4.8 million during the three-month period ended September 30, 2022.
  • Product sales decreased by 16%, or $2.3 million, to $12.4 million during the nine-month period ended September 30, 2023 compared to $14.7 million during the nine-month period ended September 30, 2022.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Retrieved on: 
火曜日, 11月 7, 2023
ICCC, Interest, Corporation, Health

PORTLAND, Maine, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2023 after the market closes on Monday, November 13, 2023.

Key Points: 
  • PORTLAND, Maine, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2023 after the market closes on Monday, November 13, 2023.
  • The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Monday, November 13, 2023.
  • The Company anticipates no change to the preliminary sales results for the third quarter of 2023 that were disclosed on October 5, 2023.
  • The Company has scheduled a conference call the next morning, Tuesday, November 14, 2023, at 9:00 AM ET to review its third quarter financial results.

ImmuCell Announces Submission of CMC Technical Section to the FDA

Retrieved on: 
火曜日, 8月 29, 2023
CMC, Disclosure, Health, FDA, Chemistry, ICCC

PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA.

Key Points: 
  • PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA.
  • On August 10, 2023, the Company issued a disclosure stating that it anticipated making this submission “shortly” after the filing of its Quarterly Report on Form 10-Q.
  • “For the benefit of clarity, we want to inform investors that this important step in the regulatory process was taken on August 18, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell.
  • “This kind of submission is subject to a six-month review by the FDA, and we are excited about the opportunity ahead.”

NEC to Pioneer Intelligent Transportation System in India's UPSRTC Buses

Retrieved on: 
水曜日, 8月 9, 2023
NEC, Travel, Passenger information system, Municipal governance in India, VLT, AIS, UPSRTC, Automatic vehicle location, ICCC, Uttar Pradesh State Road Transport Corporation, City, Kingdom, 2012 Delhi gang rape and murder, Safety, Rail transport

TOKYO, Aug 9, 2023 - (JCN Newswire) - NEC Corporation (NEC) today announced that NEC India has been selected as the master system integrator by Uttar Pradesh State Road Transport Corporation (UPSRTC) for the Vehicle Location Tracking-Passenger Information System (VLT-PSIS) project under the Nirbhaya fund of the Government of India.

Key Points: 
  • TOKYO, Aug 9, 2023 - (JCN Newswire) - NEC Corporation (NEC) today announced that NEC India has been selected as the master system integrator by Uttar Pradesh State Road Transport Corporation (UPSRTC) for the Vehicle Location Tracking-Passenger Information System (VLT-PSIS) project under the Nirbhaya fund of the Government of India.
  • This ambitious project aims to address the crucial safety concerns in buses while elevating the overall travel experience of passengers through the implementation of advanced cutting-edge technologies.
  • Notably, the project will pioneer a groundbreaking initiative in Uttar Pradesh, one of the most populous states of India, by introducing live tracking of buses through an Integrated Command Control Centre (ICCC).
  • Alongside the implementation of a well-equipped state-of-the-art ICCC solution at UPSRTC headquarters in Lucknow, 20 regional viewing centers will also be established in regional headquarters of the UPSRTC.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

Retrieved on: 
木曜日, 8月 10, 2023
Press release, Marketing, First, EBITDA, Investment, Risk, ICCC, Security (finance), FDA, Health, Recurrence, Cryptocurrency, Risk management

PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.

Key Points: 
  • PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.
  • “Our unaudited, preliminary product sales were first reported on July 11, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell.
  • During the trailing four-month period ended August 4, 2023, all three quality control tests have met standards 100% of the time.
  • Product sales decreased by 29%, or $2.9 million, to $7.0 million during the six-month period ended June 30, 2023 compared to $9.9 million during the six-month period ended June 30, 2022.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Retrieved on: 
月曜日, 8月 7, 2023
Interest, Health, Corporation, ICCC

PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023.

Key Points: 
  • PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023.
  • The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.
  • The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Thursday, August 10, 2023.
  • The Company anticipates no change to the preliminary sales results for the second quarter of 2023 that were disclosed on July 11, 2023.